healthcare

healthcare Articles

Biogen may be on track to be one of the first companies with a meaningful treatment for Alzheimer’s disease, and this could have huge implications for the stock.
Many hospitals shut down elective surgeries and other activities to brace for the impact of COVID-19. However, analysis on these shutdowns is yielding some interesting insight.
Corvus Pharmaceuticals watched the COVID-19 stock bump play out in Tuesday’s session as this company joins the ever-growing list of coronavirus stocks.
Novavax and Regeneron Pharmaceuticals each made solid progress on Tuesday after each company received a sizable capital injection from the U.S. government’s Operation Warp Speed program.
24/7 Wall Street has picked out a few of the best and brightest coronavirus stocks that could still see a big push as 2020 continues.
Here is a look of a few of the biggest clinical trial and FDA updates to watch for in July 2020.
This analyst expects that Herbalife will benefit from increased consumer interest in overall health and fitness. Plus, it has a new chief executive officer.
Akero Therapeutics has been public for only about a year now, and despite shares surging over 30% to an all-time high in Wednesday’s session, analysts think this stock can go much higher.
Pfizer and BioNTech have been collaborating to produce a messenger RNA based vaccine for the past few months, and this work is yielding promising results.
T2 Biosystems solidified its position as a coronavirus stock on Wednesday morning when it announced the launch of its COVID-19 molecular diagnostic test.
Zynerba Pharmaceuticals shares were practically halved on Tuesday on news that its cannabis-based gel did not see statistically significant results from its most recent study.
OptiNose shares popped on Tuesday after the company announced that it is making a move toward fighting COVID-19 with its tech.
Alterity Therapeutics says it has received an update from the FDA regarding its Parkinson’s treatment. That made shareholders happy.
9 Meters Biopharma may not be a household name right now, but one brokerage firm sees huge potential upside.
These are four top telehealth plays for growth investors that offer a way to not only catch the swelling trend but to have a health care position for portfolios that should remain strong for the rest...